profit from every $100 of sales.
$0$100
Medifast
$12.97+0.86% today
+13.2% in 1 year
1-year low $9.451-year high $13.37
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Medifast sold, what it kept, and what it did with the cash.
Sales went from $1.60 billion in 2022 to $386 million in 2025, with -$18.7 million of profit last year.
SalesProfit
Medifast handed back 45% of the cash it generated last year.
Buybacks $369,000$195,000
Free cash flow 2025$1M
Bought back its own shares$369,000
Paid as dividends$195,000
Cash vs. debt$89M vs. $11M
Medifast vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Medifast | No profit yet | ||
 Rollins | 35.3× · Expensive | ||
 Frontdoor | 25.6× · Fair price | ||
 H&R Block | 8.3× · Cheap | ||
 Bright Horizons Family Solutions | 13.1× · Cheap |
AI analysis
An AI analyst reads Medifast's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,599 | 1,072 | 602 | 386 | |
| 1,140 | 776 | 445 | 275 | |
| 185 | 126 | 3 | -14 | |
| 196 | 140 | 16 | 0 | |
| 144 | 99 | 2 | -19 | |
| 12.73 | 9.10 | 0.19 | -1.70 | |
| 71.3% | 72.4% | 73.8% | 71.3% | |
| 11.6% | 11.8% | 0.5% | -3.7% | |
| 9.0% | 9.3% | 0.3% | -4.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 316 | 310 | 284 | 248 |
| Cash | 88 | 94 | 91 | 89 |
| Total debt | 26 | 22 | 16 | 11 |
| Total liabilities | 161 | 108 | 74 | 49 |
| 155 | 201 | 210 | 199 | |
| 11 | 11 | 11 | 11 | |
| 80.6% | 44.7% | 1.0% | -5.4% | |
| 92.6% | 49.3% | 1.0% | -9.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 195 | 148 | 24 | 7 | |
| 17 | 6 | 7 | 6 | |
| 178 | 141 | 17 | 1 | |
| Dividends paid | 72 | 73 | 1 | 0 |
| 128 | 7 | 1 | 0 | |
| 11 | 8 | 7 | 8 |
Valuation
- –
- –
- –
- 0.7×
- 0.4×
- 116.1×
- 2,290.7×
- 0.9%
- -12.9%
- 0.0%
Profitability
- 71.3%
- -3.7%
- -4.8%
- 0.5%
- -6.6%
- 37.2%
- -9.7%
- -7.9%
- -6.7%
- 0.3%
Growth
- −37.7%
- –
- −92.7%
- +17.7%
- −1.6%
Financial health
- -30.4×
- 0.08
- 6.4%
- –
- 4.80
- 4.30
- 1.37
How it ranks in Consumer Discretionary
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 982
Bottom 5%of 996
Bottom 1%of 996
Bottom 21%of 982
What analysts expect
- Average price target
- $12.00
- Range
- $12.00 – $12.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 4, 2026 | -0.19 | -0.55 | +65.5% |
| Feb 17, 2026 | -0.55 | -0.76 | +27.6% |
| Nov 3, 2025 | -0.21 | -0.01 | −2,000.0% |
| Aug 4, 2025 | 0.04 | -0.30 | +113.3% |
| Apr 28, 2025 | -0.11 | -0.07 | −57.1% |
| Feb 18, 2025 | 0.10 | -0.16 | +162.5% |
| Nov 4, 2024 | 0.35 | -0.15 | +333.3% |
| Aug 5, 2024 | 0.92 | 0.36 | +155.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
40No pass
Benjamin Graham
74Pass
Philip Fisher
53No pass
Peter Lynch
32No pass
Joel Greenblatt
4No pass
Charlie Munger
58No pass
Terry Smith
50No pass
Questions about Medifast
Is Medifast a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Medifast AI analysis
What does Medifast do?
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. It is in Personal Products & Services.
Does Medifast pay a dividend?
Yes. In 2025 it paid out $195,000 in dividends.
Is Medifast stock halal?
No. Medifast does not pass our halal screen: its cash and confirmed interest-bearing investments are 62% of its market value, at or above the 33% limit. How we check
How has Medifast stock done over the past year?
Up 13.2% over the past twelve months, to $12.97. It traded between $9.45 and $13.37 and is 3.0% below its high.
Who are Medifast's competitors?
The largest listed companies in the same industry are Rollins, Frontdoor, H&R Block and Bright Horizons Family Solutions. The peers table on this page compares their profit, growth and price with Medifast's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.